Revolutionizing Inflammation Treatment
Pioneering synthetic small molecule therapies, Azalla Pharmaceuticals is addressing critical unmet medical needs in inflammation and neuroinflammation.
Our Mission and Vision:
At Azalla Pharmaceuticals, we are dedicated to understanding the potential of synthetic compounds and their ability to combat inflammation and improve lives. Our vision extends beyond our mission. We envision a future where our research leads to a new class of orally available anti-inflammatory drugs and consumer products, offering innovative solutions to unmet medical needs.
A Unique Approach
While many have taken a biological approach, we’ve ventured into the world of chemistry. Our hypothesis suggests that the mode of action can be explained by unknown compounds. We believe these compounds have clinical activity, particularly in the realm of anti-inflammatory properties.
Our Strategy
- Build a library of synthetic compounds assembled based on unique chemical properties.
- Screen X against Y, focusing on inflammation.
- Our hypothesis: Unappreciated compounds work through modulation of inflammation, explaining its broad therapeutic benefit.
Why Azalla Pharmaceuticals
- We’ve succeeded in insight generation at a fraction of the cost of traditional pharma.
- We’re dedicated to discovering valuable insights and small molecules for inflammatory conditions.
- Our discovery platform is agnostic allowing for versatile exploration of natural compound for potential therapeutic applications in inflammatory conditions.
Synthetic Compounds for Inflammation and Neuroinflammation:
Our research has identified a novel class of synthetic compounds that exhibit potent anti-inflammatory activity. We are exploring the use of these compounds as therapeutic candidates for neuroinflammation applications.
Key Findings
- Potent Anti-Inflammatory Compounds: Two synthetic compounds code-named J-019 and J-041 exhibit potent anti-inflammatory activity.
- Broad Inhibitory Activity: These compounds demonstrate significant inhibitory activity in vitro against a range of key inflammatory cytokines, including TNF-alpha, IL-1B, IFN-gamma, and IL-10, that are implicated in inflammation.
- Low Toxicity: Importantly, these compounds exhibit low in-vitro toxicity, making them suitable candidates for further development.
- High Selectivity for CB2 Receptor: Our compounds have shown good selectivity for inhibiting the CB2 receptor over the CB1 receptor, suggesting a potential mechanism for modulating neuroinflammation.
- In-Vivo Efficacy: In testing within the collagen-induced arthritis (CIA) model, J-019 and J-041 are efficacious at well-tolerated doses.